«ЭФФЕКТИВНОСТЬ АНАЛОГОВ СОМАТОСТАТИНА (САНДОСТАТИН-ЛАР) В ЛЕЧЕНИИ ГИГАНТСКИХ НЕАКТИВНЫХ АДЕНОМ ГИПОФИЗА»
Keywords:
NFPA, giant pituitary adenomas, treatment with Sandostatin LarAbstract
The purpose of the study is to study the effectiveness of Sandostatin – Lar in the treatment of giant pituitary adenoma.
Material and research methods. We studied the data of the 3x centers of Tashkent (RSSPMC Endocrinology, the Scientific Center for Neurosurgery and the Scientific Center for Emergency Medical Assistance of the PHM RUZ), according to which 68 patients with giant adenomes of the pituitary gland of various etiologies were spent in them for 3 years (2015-2017). (Of these, men are 43, women -25). Average age: men amounted to 37.12 years, women - 38, 15 years the statute of limitations ranged from 2 months to 25 years.
Research methods included: 1) general clinical (study of endocrine, neurological statuses), 2) instrumental (perimetry for all colors, eye bottom, visual acuity, 3) ECG, CT/MRI of the Turkish saddle and adrenal glands, 4) ultrasound of the internal and genitals, etc.), 5) hormonal blood tests (STH, IGF-1, LH, FSH, PRL, TSH, ACTH, prolactin, testosterone, estradiol, progesterone, cortisol (RIA serums of blood were carried out on the meters of “Gamma -12 ”and“ Strantg 300 ”). In addition, postoperative material was subjected to histological diagnosis in the RSSPMC E PHM RUZ named after Acad. Y.H. Turakulov (histology cabinet).
Results. 10 patients who received the therapy of Sandostatin Lar have a stable preservation of the medium size of the pituitary gland. While in the 2nd group- without Sandostatin Lar- there is a tendency to growth of the tumor (p <0.05)
Conclusions. Patients with giant inactive pituitary adenomas in the postoperative period should in order to prevent the growth of growth and further invasion to recommend the purpose of Sandostatin Lar for 3-6-12 months to stabilize the process.
References
Borson-Chazot F, Houzard C, Ajzenberg C, et al. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide. //Clin Endocrinol (Oxf). 1997;47:589-598.
De Bruin T, Kwekkeboom D, Van’t Verlaat J, et al. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment and studies in vitro. // J Clin Endocrinol Metab. 1992;75:1310-1317.
Chen L, White WL, Spetzler RF, Xu B. A prospective study of nonfunctioning pituitary adenomas: presentation, management, and clinical outcome. //J Neurooncol. 2011;102(1):129–138.
Ferrante E, Ferraroni M, Castrignanò T, Menicatti L, Anagni M, Reimondo G, Del Monte P, Bernasconi D, Loli P, Faustini-Fustini M, Borretta G, Terzolo M, Losa M, Morabito A, Spada A, Beck-Peccoz P, Lania AG. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. //Eur J Endocrinol. 2006;155(6):823–829.
Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML, Endocrine S; Endocrine Society . Pituitary incidentaloma: an Endocrine Society clinical practice guideline. // J Clin Endocrinol Metab. 2011;96(4):894–904.
Fusco A, Giampietro A, Bianchi A, et al. Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. // Pituitary. 2012;15:571-578.
Hyrcza MD, Ezzat S, Mete O, Asa SL. Pituitary adenomas presenting as sinonasal or nasopharyngeal masses: a case series illustrating potential diagnostic pitfalls. // Am J Surg Pathol. 2017;41(4):525–534
Karavitaki N, Collison K, Halliday J, Byrne JV, Price P, Cudlip S, Wass JA. What is the natural history of nonoperated nonfunctioning pituitary adenomas? // Clin Endocrinol (Oxf). 2007;67(6):938–943.
Korbonits M, Carlsen E. Recent clinical and pathophysiological advances in non-functioning pituitary adenomas. Horm Res. 2009;71(Suppl 2):123–130.
4. Mayson SE, Snyder PJ. Silent (clinically nonfunctioning) pituitary adenomas. //J Neurooncol. 2014;117(3):429–436.
Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, Fukuhara N, Yamaguchi-Okada M, Takeuchi Y, Yamada S. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. // Endocr Pathol. 2015;26(4):349–355.
Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. //Eur J Endocrinol. 2007;156(2):203–216.
.Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptors subtype (SSTR1–5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. //Eur J Endocrinol. 2007;156:65-74.
